Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.65 and traded as high as $0.48. Cyclacel Pharmaceuticals shares last traded at $0.48, with a volume of 2,100 shares.
CYCC has been the subject of several recent analyst reports. Roth Capital reaffirmed a “buy” rating on shares of Cyclacel Pharmaceuticals in a report on Thursday, May 23rd. Zacks Investment Research downgraded shares of Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 16th.
The company has a current ratio of 7.26, a quick ratio of 7.26 and a debt-to-equity ratio of 0.08. The company’s fifty day moving average is $0.48 and its 200-day moving average is $0.65. The firm has a market capitalization of $8.25 million, a P/E ratio of -0.81 and a beta of 3.03.
An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC raised its stake in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,102,400 shares of the biotechnology company’s stock after purchasing an additional 498,200 shares during the period. Renaissance Technologies LLC owned approximately 6.41% of Cyclacel Pharmaceuticals worth $596,000 as of its most recent SEC filing. 8.96% of the stock is currently owned by hedge funds and other institutional investors.
Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Recommended Story: Using other technical indicators with support levels
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.